Novel PI3K Inhibitors in B-Cell Malignancies

Novel PI3K Inhibitors in B-Cell Malignancies

Episodes

Specialty:

All

Year:

All

EP. 1: Treating Chronic Lymphocytic Leukemia

June 29th 2016

EP. 2: Role of PI3K-Targeted Therapy in CLL

June 29th 2016

EP. 3: Duvelisib in Relapsed/Refractory CLL

June 29th 2016

EP. 4: Encouraging Early Data for Novel PI3K Inhibitors

June 29th 2016

EP. 5: Treatment of Follicular Lymphoma

June 29th 2016

EP. 6: PI3K-Targeted Therapy for Follicular Lymphoma

June 29th 2016

EP. 7: Preliminary Data for Duvelisib in Indolent NHL

June 29th 2016

Trending on OncLive

FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer

Brachytherapy and Minimally Invasive Surgical Techniques Signal the Future of Brain Cancer Management

TP53 Co-Mutations and Prognosis in EGFR-Mutated NSCLC

Selecting Frontline Therapy for High-Risk EGFR-Mutated NSCLC

Herbert Lepor, MD, on Focal Cryotherapy, 1,000 Procedures, and Andre De Shields